WSTAM
PDLI

Wilbanks Smith & Thomas Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,320
Closed -$3K – 1581
2018
Q3 		$3K Buy
+1,320
New +$3.24K ﹤0.01% 1366

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's PDLI Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 1,320 shares — an estimated $3K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in PDLI in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 1,320 PDL BioPharma, Inc. shares in Q4 2018, an estimated $3K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in PDL BioPharma, Inc. in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's PDL BioPharma, Inc. position peaked at $3K in Q3 2018.
  • 154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.